References
- Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533–534.
- A comprehensive timeline of the new coronavirus pandemic, from China’s first COVID-19 case to the present. Business Insider. 2020. https://www.businessinsider.com/coronavirus-pandemic-timeline-history-major-events-2020-3.
- World Health Organization Declares COVID-19 a “Pandemic.” Here’s What That Means. TIME. 2020. https://time.com/5,791,661/who-coronavirus-pandemic-declaration/
- Coronavirus (COVID-19). WHO. 2020. [cited 2020 Jun 10]. https://who.sprinklr.com/
- Coronavirus (COVID-19) Update: FDA issues emergency use authorization for potential COVID-19 treatment. US-FDA. 2020. [cited 2020 Jun 4]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment.
- ClinicalTrials.gov. NIH U.S. National Library of Medicine. 2020. [cited 2020 Jun 4]. https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=vaccines&cntry=&state=&city=&dist=.
- Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. WHO. 2020 [cited 2020 Jun 4]. file:///C:/Users/Admin/Downloads/WHO-2019-nCoV-clinical-2020.4-eng.pdf.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24(1):91.
- Chen L, Xiong J, Bao L, et al. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400.
- Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus. 2016;14(2):152–157.
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80–90.
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama. 2020;323(16):1582–1589.
- Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496.
- Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020;158(1):e9–e13.
- Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID‐19 patients in Wuhan. J Med Virol. 2020;92(10):1890–1901.
- Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149.
- Joyner M, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020;130(9):4791–4797.
- Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460. [Internet].
- Recommendations for Investigational COVID-19 Convalescent Plasma. US-FDA. 2020. [cited 2020 Jun 4]. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma.
- Tanne JH. COVID-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020;368:m1256.
- Wang C, Li W, Drabek D, et al. A human monoclonal 1 antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2511.
- Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765.
- Klimpel GR. Immune defenses. In: Baron S, editor. Medical microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.
- Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect. 2020;53(3):365–367.
- Murphy M, Estcourt L, Grant-Casey J, et al. International survey of trials of convalescent plasma to treat COVID-19 infection. Transfus Med Rev. 2020;34(3):151–157.
- COVID-19 Resources. American Society of Hematology. 2020. [cited 2020 Jun 4]. https://www.hematology.org/covid-19/covid-19-and-convalescent-plasma.
- Recommendations for Investigational COVID-19 Convalescent Plasma [Internet]. US-FDA. 2020. [cited 2020 Sep 3]. Available from: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma.
- Joyner M, Senefeld J, Klassen S, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1.
- Salazar E, Perez KK, Ashraf M, et al. Treatment of COVID-19 patients with convalescent plasma in Houston, Texas. Am J Pathol. 2020;190(8):1680–1690.
- Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. J Infect Dis. 2020;222(1):38–43.
- Chen S, Lu C, Li P, et al. Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.08.02.20166710v1
- Rasheed A, Ftak D, Hashim H, et al. The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.06.24.20121905v2.
- Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;11:1–34.
- FDA Issues Emergency Use Authorization for Convalescent Plasma as Potential Promising COVID–19 Treatment, Another Achievement in Administration’s Fight Against Pandemic [Internet]. US-FDA. 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment.
- Gavriatopoulou M, Korompoki E, Fotiou D, et al. Organ-specific manifestations of COVID-19 infection. Clin Exp Med. 2020;20(4):493–494.,
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–847.
- Psaltopoulou T, Sergentanis TN, Pappa V, et al. The emerging role of convalescent plasma in the treatment of COVID-19. Hemasphere. 2020;4(3):e409.
- Joyner M, Klassen S, Senefeld J. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.07.29.20162917v2
- Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609.
- Tan L, Kang X, Zhang B, et al. A special case of COVID-19 with long duration of viral shedding for 49 days. medRxiv. 2020.
- Menis M, Sridhar G, Selvam N, et al. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008–2011. Am J Hematol. 2013;88(12):1035–1040.
- Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. Jama. 2020;323(16):1561.
- Nakajima K. Donor complications and donor care. ISBT Sci Ser. 2009;4(n2):411–417.
- Side Effects of Donating Plasma. Healthline. https://www.healthline.com/health/donating-plasma-side-effects#dehydration.
- Chen X. Commercial plasma donation and individual health in impoverished rural China. Health Econ Rev. 2014;4(1):30.
- FDA Issues Guidance Documents Directed to Blood Donations as Part of COVID-19 Public Health Emergency Measures. Seyfarth. 2020. [cited 2020 Jun 4]. https://www.seyfarth.com/news-insights/fda-issues-guidance-documents-directed-to-blood-donations-as-part-of-covid-19-public-health-emergency-measures.html
- Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554–1561.
- Van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42.
- Beigel JH, Aga E, Elie-Turenne MC, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2019;7(11):941–950.
- Crowe JE, Firestone CY, Murphy BR. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. J Immunol. 2001;167(7):3910–3918.